FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)
Source abstract
Abstract
Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outcomes in immune‐resistant lung tumors. More details can be found in article number 2202702 by Yongdoo Choi, Sung‐Ho Go, and co‐workers. [Image: see text]
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ferroptosis and cancer prognosis · Cancer Immunotherapy and Biomarkers · Cancer Mechanisms and Therapy
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References
Reference metadata was not supplied for this record.